Tradestie Institutional Equity Comparison Engine
SGP vs BMY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMY Overall Edge
BMY Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bristol-Myers Squibb Co. (BMY) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SGP trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BMY at 9.4x Forward P/E and 32.4% operating margin (+6.9% YoY). In options structure, SGP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BMY sits in CONSOLIDATION (31st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
BMY
SGP N/M vs BMY 9.4x Fwd P/E
Growth & Margin Winner
BMY
Op Margin N/A vs 32.4% ยท YoY N/A vs +6.9%
Momentum & Technical Winner
BMY
1Y +22.1% vs +29.4% ยท 52W Pos 66% vs 76%
Options & Structure Winner
BMY
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (31st %ile IV)
SGP
US Equity
SGP
Institutional Equity
$32.24
-1.95% 1D
Market Cap
N/A
1M Return
+34.33%
1Y Return
+22.12%
Forward P/E
N/M
Unified AI Score
39.3 / 100
SELL
Tech 15.0
Fund 45.0
Flow 50.0
Mom 60.0
BMY
NYSE
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
$62.93
-0.79% 1D
Market Cap
$129.7B
1M Return
+5.32%
1Y Return
+29.41%
Forward P/E
9.4x
Unified AI Score
53.5 / 100
HOLD
Tech 50.0
Fund 58.0
Flow 70.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SGP +22.12%
BMY +29.41%
Spread: +20.6 pp (SGP Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SGP TTM Op. Margin: N/A
BMY TTM Op. Margin: 32.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGP vs BMY. Trailing 12-month operating profitability (SGP N/A vs BMY 32.4%) and valuation multiples (SGP N/M vs BMY 9.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SGP | BMY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $129.7B | Larger Scale | BMY |
| Trailing P/E Ratio Valuation | N/M | 14.1x | Lower Multiple | BMY |
| Forward P/E Ratio Valuation | N/M | 9.4x | Lower Multiple | BMY |
| Revenue Growth (YoY) Growth | N/A | +6.9% | Higher Growth | BMY |
| Operating Margin (TTM) Profitability | N/A | 32.4% | Higher Margin | BMY |
| Net Profit Margin Profitability | N/A | 18.5% | Higher Margin | BMY |
| Return on Equity (ROE) Capital Efficiency | N/A | 44.0% | Higher ROE | BMY |
| 52-Week Range Position Momentum | 66% ($17โ$40) | 76% ($45โ$69) | Stronger Trend | BMY |
| Beta / 30D Volatility Risk Regime | 1.38ฮฒ ยท 70% Vol | 0.17ฮฒ ยท 31% Vol | Lower Realized Risk | BMY |
| Unified Institutional Score Composite Signal | 39.3 / 100 (SELL) | 53.5 / 100 (HOLD) | Higher Composite | BMY |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SGP vs BMY Buy Guide
SGP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BMY
CONSOLIDATION
51d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
31st %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SGP nor BMY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.